Legato Capital Management LLC raised its position in Core Scientific, Inc. (NASDAQ:CORZ - Free Report) by 51.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 118,497 shares of the company's stock after acquiring an additional 40,493 shares during the quarter. Legato Capital Management LLC's holdings in Core Scientific were worth $1,665,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently made changes to their positions in the business. Joel Isaacson & Co. LLC boosted its stake in shares of Core Scientific by 4.5% during the 4th quarter. Joel Isaacson & Co. LLC now owns 58,011 shares of the company's stock valued at $815,000 after buying an additional 2,500 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new position in shares of Core Scientific during the 4th quarter valued at approximately $42,000. Vontobel Holding Ltd. boosted its stake in shares of Core Scientific by 10.4% during the 3rd quarter. Vontobel Holding Ltd. now owns 38,089 shares of the company's stock valued at $452,000 after buying an additional 3,591 shares during the last quarter. Harvest Portfolios Group Inc. boosted its stake in shares of Core Scientific by 10.1% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 55,881 shares of the company's stock valued at $663,000 after buying an additional 5,109 shares during the last quarter. Finally, Pekin Hardy Strauss Inc. boosted its stake in shares of Core Scientific by 25.4% during the 3rd quarter. Pekin Hardy Strauss Inc. now owns 30,725 shares of the company's stock valued at $364,000 after buying an additional 6,225 shares during the last quarter.
Analysts Set New Price Targets
CORZ has been the topic of several research analyst reports. Roth Capital upgraded Core Scientific to a "strong-buy" rating in a research note on Thursday, November 14th. Needham & Company LLC restated a "buy" rating and set a $18.00 price objective on shares of Core Scientific in a research note on Friday, January 17th. Craig Hallum initiated coverage on Core Scientific in a research note on Tuesday, January 21st. They set a "buy" rating and a $24.00 price objective on the stock. BTIG Research raised their price objective on Core Scientific from $19.00 to $20.00 and gave the stock a "buy" rating in a research note on Monday, December 16th. Finally, Keefe, Bruyette & Woods initiated coverage on Core Scientific in a research note on Monday, January 27th. They set an "outperform" rating and a $22.00 price objective on the stock. Fifteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $19.07.
Get Our Latest Analysis on CORZ
Insider Activity
In related news, insider Todd M. Duchene sold 25,000 shares of Core Scientific stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $17.10, for a total transaction of $427,500.00. Following the transaction, the insider now directly owns 1,661,474 shares of the company's stock, valued at $28,411,205.40. The trade was a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Adam Taylor Sullivan sold 369,712 shares of Core Scientific stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $16.24, for a total value of $6,004,122.88. Following the transaction, the chief executive officer now directly owns 3,758,793 shares in the company, valued at approximately $61,042,798.32. The trade was a 8.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 744,032 shares of company stock valued at $11,863,966. Company insiders own 32.00% of the company's stock.
Core Scientific Price Performance
Shares of CORZ traded down $0.03 during trading hours on Friday, reaching $12.51. 4,093,882 shares of the company's stock traded hands, compared to its average volume of 12,171,637. The firm has a market capitalization of $3.49 billion and a price-to-earnings ratio of -2.31. Core Scientific, Inc. has a twelve month low of $2.61 and a twelve month high of $18.63. The business's fifty day simple moving average is $14.16 and its two-hundred day simple moving average is $13.14.
Core Scientific Profile
(
Free Report)
Core Scientific, Inc provides digital asset mining services in North America. It operates through two segments, Mining and Hosting. The company offers blockchain infrastructure, software solutions, and services; and operates data center mining facilities. It also mines digital assets for its own account; and provides hosting services for other large bitcoin miners, which include deployment, monitoring, trouble shooting, optimization, and maintenance of its customers' digital asset mining equipment.
Featured Articles

Before you consider Core Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Core Scientific wasn't on the list.
While Core Scientific currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.